Expanding targeted therapy to NRAS-mutated melanoma

被引：3
作者：
Gibney, Geoffrey T. [1 ]
Weber, Jeffrey S.
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Cutaneous Oncol, Tampa, FL 33612 USA
来源：
LANCET ONCOLOGY | 2013年 / 14卷 / 03期
关键词：
METASTATIC MELANOMA; IMPROVED SURVIVAL; MEK INHIBITION; OPEN-LABEL; BRAF; TRIAL; SELUMETINIB; MUTATIONS;
D O I：
10.1016/S1470-2045(13)70054-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：186 / 188
页数：4
相关论文
共 12 条
  • [1] Ascierto PA, 2013, LANCET ONCOL
  • [2] High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993
    Atkins, MB
    Lotze, MT
    Dutcher, JP
    Fisher, RI
    Weiss, G
    Margolin, K
    Abrams, J
    Sznol, M
    Parkinson, D
    Hawkins, M
    Paradise, C
    Kunkel, L
    Rosenberg, SA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) : 2105 - 2116
  • [3] Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
    Chapman, Paul B.
    Hauschild, Axel
    Robert, Caroline
    Haanen, John B.
    Ascierto, Paolo
    Larkin, James
    Dummer, Reinhard
    Garbe, Claus
    Testori, Alessandro
    Maio, Michele
    Hogg, David
    Lorigan, Paul
    Lebbe, Celeste
    Jouary, Thomas
    Schadendorf, Dirk
    Ribas, Antoni
    O'Day, Steven J.
    Sosman, Jeffrey A.
    Kirkwood, John M.
    Eggermont, Alexander M. M.
    Dreno, Brigitte
    Nolop, Keith
    Li, Jiang
    Nelson, Betty
    Hou, Jeannie
    Lee, Richard J.
    Flaherty, Keith T.
    McArthur, Grant A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (26) : 2507 - 2516
  • [4] Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
    Dry, Jonathan R.
    Pavey, Sandra
    Pratilas, Christine A.
    Harbron, Chris
    Runswick, Sarah
    Hodgson, Darren
    Chresta, Christine
    McCormack, Rose
    Byrne, Natalie
    Cockerill, Mark
    Graham, Alexander
    Beran, Garry
    Cassidy, Andrew
    Haggerty, Carolyn
    Brown, Helen
    Ellison, Gillian
    Dering, Judy
    Taylor, Barry S.
    Stark, Mitchell
    Bonazzi, Vanessa
    Ravishankar, Sugandha
    Packer, Leisl
    Xing, Feng
    Solit, David B.
    Finn, Richard S.
    Rosen, Neal
    Hayward, Nicholas K.
    French, Tim
    Smith, Paul D.
    [J]. CANCER RESEARCH, 2010, 70 (06) : 2264 - 2273
  • [5] Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
    Falchook, Gerald S.
    Lewis, Karl D.
    Infante, Jeffrey R.
    Gordon, Michael S.
    Vogelzang, Nicholas J.
    DeMarini, Douglas J.
    Sun, Peng
    Moy, Christopher
    Szabo, Stephen A.
    Roadcap, Lori T.
    Peddareddigari, Vijay G. R.
    Lebowitz, Peter F.
    Le, Ngocdiep T.
    Burris, Howard A., III
    Messersmith, Wells A.
    O'Dwyer, Peter J.
    Kim, Kevin B.
    Flaherty, Keith
    Bendell, Johanna C.
    Gonzalez, Rene
    Kurzrock, Razelle
    Fecher, Leslie A.
    [J]. LANCET ONCOLOGY, 2012, 13 (08) : 782 - 789
  • [6] Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
    Flaherty, Keith T.
    Infante, Jeffery R.
    Daud, Adil
    Gonzalez, Rene
    Kefford, Richard F.
    Sosman, Jeffrey
    Hamid, Omid
    Schuchter, Lynn
    Cebon, Jonathan
    Ibrahim, Nageatte
    Kudchadkar, Ragini
    Burris, Howard A., III
    Falchook, Gerald
    Algazi, Alain
    Lewis, Karl
    Long, Georgina V.
    Puzanov, Igor
    Lebowitz, Peter
    Singh, Ajay
    Little, Shonda
    Sun, Peng
    Allred, Alicia
    Ouellet, Daniele
    Kim, Kevin B.
    Patel, Kiran
    Weber, Jeffrey
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (18) : 1694 - 1703
  • [7] Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
    Flaherty, Keith T.
    Robert, Caroline
    Hersey, Peter
    Nathan, Paul
    Garbe, Claus
    Milhem, Mohammed
    Demidov, Lev V.
    Hassel, Jessica C.
    Rutkowski, Piotr
    Mohr, Peter
    Dummer, Reinhard
    Trefzer, Uwe
    Larkin, James M. G.
    Utikal, Jochen
    Dreno, Brigitte
    Nyakas, Marta
    Middleton, Mark R.
    Becker, Juergen C.
    Casey, Michelle
    Sherman, Laurie J.
    Wu, Frank S.
    Ouellet, Daniele
    Martin, Anne-Marie
    Patel, Kiran
    Schadendorf, Dirk
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (02) : 107 - 114
  • [8] Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
    Hauschild, Axel
    Grob, Jean-Jacques
    Demidov, Lev V.
    Jouary, Thomas
    Gutzmer, Ralf
    Millward, Michael
    Rutkowski, Piotr
    Blank, Christian U.
    Miller, Wilson H., Jr.
    Kaempgen, Eckhart
    Martin-Algarra, Salvador
    Karaszewska, Boguslawa
    Mauch, Cornelia
    Chiarion-Sileni, Vanna
    Martin, Anne-Marie
    Swann, Suzanne
    Haney, Patricia
    Mirakhur, Beloo
    Guckert, Mary E.
    Goodman, Vicki
    Chapman, Paul B.
    [J]. LANCET, 2012, 380 (9839) : 358 - 365
  • [9] Correlation of NRAS Mutations With Clinical Response to High-dose IL-2 in Patients With Advanced Melanoma
    Joseph, Richard W.
    Sullivan, Ryan J.
    Harrell, Robyn
    Stemke-Hale, Katherine
    Panka, David
    Manoukian, George
    Percy, Andrew
    Bassett, Roland L.
    Ng, Chaan S.
    Radvanyi, Laszlo
    Hwu, Patrick
    Atkins, Michael B.
    Davies, Michael A.
    [J]. JOURNAL OF IMMUNOTHERAPY, 2012, 35 (01) : 66 - 72
  • [10] Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma
    Kirkwood, John M.
    Bastholt, Lars
    Robert, Caroline
    Sosman, Jeff
    Larkin, James
    Hersey, Peter
    Middleton, Mark
    Cantarini, Mireille
    Zazulina, Victoria
    Kemsley, Karin
    Dummer, Reinhard
    [J]. CLINICAL CANCER RESEARCH, 2012, 18 (02) : 555 - 567
12